Publication

[Cancer Science] Scientists identified Glycogen synthase kinase 3 (GSK3) as a therapeutic target through a whole-body genetic screening utilizing a ‘4-hit’ Drosophila model mimicking the PDAC genotype.

[Cell Stem Cell] Investigators reported that allogeneic transplantation of genetically engineered, primary, hypoimmune, pseudo-islets resulted in their engraftment into a fully immunocompetent, diabetic non-human primate wherein they provided stable endocrine function and enabled insulin independence without inducing any detectable immune response in the absence of immunosuppression.

[Nature Communications] Investigators identified Tyrosinase Related Protein 1 as a CAR-T cell therapy target to treat patients with cutaneous and rare melanoma subtypes unresponsive to immune checkpoint blockade.

[Advanced Healthcare Materials] Scientists developed a cell membrane-targeting photosensitizer, TBzT-CNQi, which could generate 1O2, •OH, and O2•− via type I/II process to induce a high level of lipid peroxide for potent ferroptosis and photodynamic therapy.

[Journal Of Pathology] Researchers found that a knock-in mouse with a missense S1P lyase (SPL) mutation mimicking human disease resulted in reduced SPL activity, increased S1P, increased TGF-β signaling, increased lung fibrosis, and higher mortality after injury compared to wild type.

[Journal Of Biomedical Science] Albumin-conjugated FLT3L (Alb-FLT3L) was generated and applied for translational medicine purposes; here it was used to treat naïve C57BL/6 and OT1 mice for CD8 T cell response analysis. Syngeneic B16ova and E.G7ova mouse models were employed for adoptive cell transfer to evaluate the effects of Alb-FLT3L preconditioning of CD8 T cells on tumor progression.